Live
- Nani unveils ‘MM 2’ title & first look
- Will challenge bail granted to actor Darshan in fan murder case in SC: Bengaluru Police Commissioner
- Chandrahass Launches Maruti Suzuki Dzire Through PJ Productions in Tolichowki Showroom
- Police case against farmers for tilling land claimed by Waqf Board in Karnataka
- Commendable move: Sandeep Dikshit on renaming Sarai Kale Khan ISBT chowk after Birsa Munda
- MahaYuti will come back to power with a thumping majority despite Oppn's tirade: Eknath Shinde
- ‘Hanging up my racquet. Thank you’ - India’s Prajnesh Gunneswaran retires from professional tennis
- Pawan Kalyan to Campaign for NDA Alliance in Maharashtra
- Eight killed, five injured in Nepal's traffic accident
- Technical snag grounds PM Modi's aircraft in Jharkhand
Aurobindo Pharma Ltd gets FDA nod for new drug
Aurobindo Pharma Ltd has announced the receipt of final approval from the US Food and Drug Administration (USFDA) to manufacture and market Norethindrone Acetate tablets in 5 mg strengths.
​ Hyderabad: Aurobindo Pharma Ltd has announced the receipt of final approval from the US Food and Drug Administration (USFDA) to manufacture and market Norethindrone Acetate tablets in 5 mg strengths. The drug is bioequivalent and therapeutically-equivalent of Aygestin tablets made by US-based Duramed Pharmaceuticals, the company said in a filing.
The drug is used in the treatment of endometriosis, or uterine bleeding caused by abnormal hormone levels and secondary amenorrhea. The approved product has an estimated market size of $24 million for the 12 months ending November 2016.
Aurobindo said this is the 57th ANDA to be approved out of its VII unit formulation plant in Hyderabad for manufacturing oral non-antibiotic products. The company now has 230 ANDA approvals, it added.
